Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.

Drug monitoring is recommended to identify patients with insufficient ASNase trough activities in serum and to modify the treatment schedule, if necessary. Shortening of the treatment interval might be preferable over increasing the rASNase dose.